Cytokinetics CEO sells 7,500 shares
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $77.92 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $77.92 per share. After this transaction, he directly holds 400,330 shares. Separate from his direct position, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares
Net Sell
3 txns
Insider
Blum Robert I
Role
President & CEO
Sold
7,500 shs ($584K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,500 | $77.92 | $584K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 400,330 shares (Direct);
Common Stock — 2,083 shares (Indirect, by Trust 1);
Common Stock — 2,083 shares (Indirect, by Trust 2)
Footnotes (2)
- F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
- F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Key Figures
Shares sold: 7,500 shares
Sale price: $77.92 per share
Direct holdings after transaction: 400,330 shares
+3 more
6 metrics
Shares sold
7,500 shares
Open-market sale of Common Stock
Sale price
$77.92 per share
Price for 7,500-share sale
Direct holdings after transaction
400,330 shares
Common Stock held directly by CEO after sale
Bridget Blum Trust holdings
2,083 shares
Indirect ownership via The Bridget Blum 2003 Irrevocable Trust
Brittany Blum Trust holdings
2,083 shares
Indirect ownership via The Brittany Blum 2003 Irrevocable Trust
Net buy/sell direction
Net-sell of 7,500 shares
Summary of reported insider activity
Key Terms
open-market sale, indirect ownership, Irrevocable Trust, Form 4
4 terms
open-market sale financial
"reported an open-market sale of 7,500 shares of Common Stock at $77.92 per share"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"reported as indirect ownership positions associated with Robert I. Blum"
Irrevocable Trust financial
"held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
Form 4 regulatory
"according to a Form 4 insider trading report filed with regulators"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CYTOKINETICS (CYTK) report for CEO Robert Blum?
CYTOKINETICS reported that President & CEO Robert I. Blum sold 7,500 shares of Common Stock in an open-market transaction at $77.92 per share, according to a Form 4 insider trading report filed with regulators.
Were there any indirect CYTOKINETICS (CYTK) holdings reported for Robert Blum in this Form 4?
Yes. The Form 4 shows 2,083 CYTOKINETICS shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, both reported as indirect ownership positions associated with Robert I. Blum.
Does the CYTOKINETICS (CYTK) Form 4 include any option exercises or derivative transactions?
No. The Form 4 for CYTOKINETICS only reports a non-derivative open-market sale of Common Stock and separate indirect trust holdings. The derivative summary section in the provided data shows no derivative transactions or option exercises.
AI-generated analysis. How Rhea-AI works. Not financial advice.
